Walford GA, Porneala BC, Dauriz M, et al. Metabolite traits and genetic risk provide complementary information for the prediction of future type 2 diabetes. Diabetes Care. 2014;37(9):2508-14. doi:10.2337/dc14-0560
Miao J, Ling AV, Manthena PV, et al. Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nat Commun. 2015;6:6498. doi:10.1038/ncomms7498
Imamura M, Takahashi A, Yamauchi T, et al. Genome-wide association studies in the Japanese population identify seven novel loci for type 2 diabetes. Nat Commun. 2016;7:10531. doi:10.1038/ncomms10531
Meier BC, Wagner BK. Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics. Epigenomics. 2014;6(2):209-14. doi:10.2217/epi.14.11
Florez JC, Jablonski KA, McAteer JB, et al. Effects of genetic variants previously associated with fasting glucose and insulin in the Diabetes Prevention Program. PLoS One. 2012;7(9):e44424. doi:10.1371/journal.pone.0044424
Pawlyk AC, Giacomini KM, McKeon C, Shuldiner AR, Florez JC. Metformin pharmacogenomics: current status and future directions. Diabetes. 2014;63(8):2590-9. doi:10.2337/db13-1367
Lundh M, Galbo T, Poulsen SS, Mandrup-Poulsen T. Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats. Diabetes Obes Metab. 2015;17(7):703-7. doi:10.1111/dom.12470
Clapham KR, Chu AY, Wessel J, et al. A null mutation in ANGPTL8 does not associate with either plasma glucose or type 2 diabetes in humans. BMC Endocr Disord. 2016;16:7. doi:10.1186/s12902-016-0088-8
Vetere A, Choudhary A, Burns SM, Wagner BK. Targeting the pancreatic β-cell to treat diabetes. Nat Rev Drug Discov. 2014;13(4):278-89. doi:10.1038/nrd4231
Trynka G, Sandor C, Han B, et al. Chromatin marks identify critical cell types for fine mapping complex trait variants. Nat Genet. 2013;45(2):124-30. doi:10.1038/ng.2504